Related Experiment Video
Updated: Apr 29, 2026

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
Published on: June 6, 2025
Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences?
Peter R Carroll1, Andrew J Vickers1
1Presented by Peter R. Carroll, MD, MPH, Professor and Chair, Department of Urology, University of California, San Francisco, San Francisco, California, and Andrew J. Vickers, PhD, Attending Research Methodologist, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City, and Professor of Medicine, Weill Medical College of Cornell University, New York City, New York.
Abstract:
Few clinical issues have polarized the oncology community as much as screening for prostate cancer, with advocates of prostate-specific antigen (PSA) testing vocal on one side and skeptics just as vocal on the other. At the NCCN 19th Annual Conference, Dr. Peter R. Carroll and Dr. Andrew J. Vickers tackled the controversy surrounding early detection of prostate cancer, focusing attention on the randomized trial results at the heart of the matter; over-detection (the Achilles' heel of screening); and the rationale behind the new, streamlined 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection, which emphasize selective early detection and treatment and are tightly aligned with the NCCN Guidelines for Prostate Cancer.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Cancer Prevention
Some...
Cancer Prevention

